UK-based OKYO Pharma to Relocate Listing to New York Stock Exchange from London

British biopharmaceutical company OKYO Pharma has announced that it will be leaving London’s stock market and moving its listing to New York. OKYO Pharma attributed this decision to weak trading volumes and low valuations. As a result of the move, the firm’s shares dropped by as much as 25% in trading.

This movement follows recent decisions by other major companies, such as chip designer Arm, betting company Flutter Entertainment, and construction materials company CRH, to leave the London Stock Exchange for the United States.

OKYO Pharma, which focuses on ophthalmology, will be giving its shareholders the option of consolidating existing shares into a new share matching its current American Depositary Shares, which would then be listed on NASDAQ in place of the ADS. This delisting is set to happen on May 12, 2021.

Having already successfully listed on the London Stock Exchange back in 2021, Oxford Nanopore has also cited potential additional listing options in the United States. In response to this shift of major companies, Britain’s financial watchdog has implemented measures to help London retain its allure for stock market listings.

OKYO Pharma is a British biopharmaceutical company with a focus on ophthalmology. Founded in 2015, the company has established itself as a leading player in the development of novel treatments for ophthalmic diseases. The company is now actively researching and developing new therapies, enhancing the safety and efficacy of existing treatments, and expanding into new disease states. OKYO Pharma’s products are sold across the United States, Europe, and Asia.

Yasuyuki Oda, founder and Chief Executive Officer (CEO) of OKYO Pharma, has been instrumental in driving the firm’s growth and expansion. An accomplished pharmaceutical executive with over two decades of experience, Oda spent many years as a senior executive at Astellas Pharma before launching OKYO Pharma. Oda holds numerous professional certifications, including Master of Pharmaceutical Substance Development and a Certified Merger & Acquisition Professional. Oda’s extensive experience and leadership have enabled OKYO Pharma to make the move to Nasdaq, allowing the company to more efficiently access capital and further expand its global footprint.